Tiejun Gong

Harbin, 150010, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.

Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Published: January 23, 2026

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

Journal: The oncologist

Published: December 23, 2025

TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study.

TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: November 25, 2025

HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.

HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.

Journal: Journal of proteome research

Published: November 24, 2025

Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.

Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.

Journal: Cancer

Published: July 14, 2025

The clinical utility and prognostic value of next-generation sequencing for measurable residual disease assessment in acute myeloid leukemia.

The clinical utility and prognostic value of next-generation sequencing for measurable residual disease assessment in acute myeloid leukemia.

Journal: Therapeutic advances in hematology

Published: January 02, 2025

Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations.

Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 19, 2024

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.

Journal: Med (New York, N.Y.)

Published: August 07, 2024

Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.

Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.

Journal: The Lancet. Haematology

Published: August 01, 2024

Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019.

Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019.

Journal: Chinese medical journal

Published: April 19, 2023

IDH2 regulates U2AF1 expression and hydroxymethylation in MDS patients.

IDH2 regulates U2AF1 expression and hydroxymethylation in MDS patients.

Journal: Biotechnology & genetic engineering reviews

Published: March 21, 2023

Quercetin Inhibits KBM7R Cell Proliferation through Wnt/β-Catenin Signaling.

Quercetin Inhibits KBM7R Cell Proliferation through Wnt/β-Catenin Signaling.

Journal: Evidence-based complementary and alternative medicine : eCAM

Published: May 06, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026